文献速递肝病

综述:COVID-19与肝病——截至2020年5月1日的已知信息

Review article: COVID-19 and liver disease-what we know on 1st May 2020.
PubMed 文献 · Aliment Pharmacol Ther · 2020-06-02

该综述通过检索PubMed文献,总结SARS-CoV-2感染期间肝功能检查变化及COVID-19对慢性肝病(CLD)患者的影响。结论认为COVID-19常伴转氨酶等肝功能异常,但多为轻度、一过性,临床显著肝损伤少见;肝硬化、肝癌、非酒精性脂肪性肝病、自身免疫性肝病或肝移植患者可能有更高重症COVID-19风险。

要点

  • COVID-19相关肝功能异常常见,以转氨酶升高为主,多为一过性且程度轻。
  • 肝损伤可能源于病毒直接致病、全身炎症或常用药物毒性。
  • CLD患者感染风险似不更高,但肝硬化、肝癌、NAFLD、自身免疫性肝病或肝移植者重症风险可能更高。

核心结论

  • COVID-19病程中肝功能检查异常常见,但临床显著的肝损伤少见。
  • 需进一步研究既有肝脏合并症对COVID-19治疗与结局的影响。

研究设计与样本

  • 文献综述,检索在线数据库PubMed,检索词为「SARS-CoV-2」「COVID-19」「liver」「cirrhosis」「liver transplantation」。

主要发现

  • COVID-19常伴不同程度肝功能检查异常,最突出为转氨酶,通常为一过性且程度轻。
  • 肝损伤可能由病毒直接致病作用、全身炎症或该人群常用药物毒性所致。
  • 儿童SARS-CoV-2感染伴肝酶升高轻微或无升高,肝功能异常时应评估潜在肝病。
  • CLD患者似不更高危获得感染,但肝硬化、肝细胞癌、非酒精性脂肪性肝病、自身免疫性肝病或肝移植者可能有更高重症COVID-19风险。

临床怎么用

  • COVID-19患者出现肝功能异常时,应结合用药与全身炎症评估,并排查潜在肝病。
  • 对肝硬化、肝癌、NAFLD、自身免疫性肝病及肝移植患者应警惕重症COVID-19风险。

局限性

  • 为文献综述,未提供系统检索策略、纳入研究数量及定量合并结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), became a global threat to human health. Liver impairment has been frequently reported as a common manifestation, although its clinical significance is still unclear, particularly in patients with underlying chronic liver disease (CLD). AIMS: To summarise the changes in liver function tests during SARS-CoV-2 infection and the impact of COVID-19 in patients with underlying CLD. METHODS: A literature review using online database PubMed was done using the search terms "SARS-CoV-2", "COVID-19", "liver", "cirrhosis" and "liver transplantation". RESULTS: COVID-19 is frequently associated with different degrees of abnormal liver function tests, most notably transaminases, which are usually transitory and of mild degree. Available evidence suggests that liver injury may result from direct pathogenic effect by the virus, systemic inflammation or toxicity from commonly used drugs in this subset of patients. SARS-CoV-2 infection in children is associated with minimal or no increase in liver enzymes, thus the presence of abnormal liver function tests should trigger evaluation for underlying liver diseases. Although it seems that patients with CLD are not at greater risk for acquiring the infection, those with cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease, autoimmune liver diseases or liver transplant may have a greater risk for severe COVID-19. CONCLUSIONS: Abnormal liver function tests during the course of COVID-19 are common, though clinically significant liver injury is rare. Further research is needed focusing on the effect of existing liver-related comorbidities on treatment and outcome of COVID-19.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Garrido I, Liberal R, Macedo G, et al. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020. PMID: 32402090. doi:10.1111/apt.15813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。